Julian Hofmann


Julian Hofmann has written about pharma and biotech for the past 15 years and started his career as a German-speaking reporter with Scrip Pharmaceutical News reporting on the German pharma and nascent biotech sector in the early 2000s. He then joined ThomsonReuters as a correspondent covering the UK pharma sector and later moved to the Investors Chronicle to highlight investment opportunities in the sector for the retail investor market. He champions investor education on the subject and regularly contributes to a range of general and specialist financial publications.

Sorry, there is no news by Julian Hofmann